EU agency recommends new drugs from Roche, Biogen and PTC

European regulators said on Friday they had recommended approval of Roche's drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukemia, boosting the Swiss group's line-up of new cancer treatments.

_0">

The new medicine is an improved follow-on medicine to Roche's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.

The European Medicines Agency also gave a green light to Biogen Idec's Plegridy for multiple sclerosis and a recommendation for conditional approval to PTC Therapeutics' Translarna for Duchenne muscular dystrophy.

Shares in PTC soared on the green light.

class="mandelbrot_refrag">Novartis received a mixed bag of news, with its Alcon eyecare unit winning a recommendation for Simbrinza, a treatment for open-angle glaucoma or ocular hypertension, but heart treatment serelaxin was rebuffed once again following further re-examination by EU experts.

Recommendations for class="mandelbrot_refrag">marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

(Reporting by Ben Hirschler; Editing by Paul Sandle, Greg Mahlich)

Popular posts from this blog

'I was his Christian Grey fantasy.' Ex-girlfriend Paige Lorenze says Armie Hammer carved an A into her groin area as she warns 'narcissistic' actor could 'seriously injure another woman' with his BDSM obsession

Model Stella Tennant dies 'suddenly' aged 50 as her family pay tribute to 'wonderful woman and an inspiration to us all'

Teenage boy, 15, charged after allegedly having sex with two 12-year-old girls and recording the encounter on his phone - but he's still allowed to go to school with them while on bail